Late Phase II Study of TS-142 in Patients with Insomnia

PHASE2CompletedINTERVENTIONAL

Enrollment

179

Participants

Timeline

Start Date

September 9, 2020

Primary Completion Date

November 16, 2021

Study Completion Date

November 16, 2021

Conditions

Patients with Insomnia

Interventions

DRUG

TS-142

Participants received multiple-dose of 2.5, 5, 10 mg of TS-142 or placebo (oral tablet)

Trial Locations (1)

Taisho Pharmaceutical Co., Ltd selected site, Tokyo

All Listed Sponsors

lead

Taisho Pharmaceutical Co., Ltd.

INDUSTRY

NCT04469023 - Late Phase II Study of TS-142 in Patients with Insomnia | Biotech Hunter | Biotech Hunter